April 10 (Reuters) - The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant ...
New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...
FlowCam uses Flow Imaging Microscopy (FIM) to characterize particles in liquid biopharmaceutical formulations. There are several important features of FIM instruments to keep in mind if you are ...
The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback